DRL launches generic sofosbuvir & velpatasvir tablets for HCV in India
Posted on15 May 2017
TagsDr. Reddy’s Laboratories, DRL, Sofosbuvir, sofosbuvir & velpatasvir tablets, sofosbuvir/velpatasvir/voxilaprevir
Comments0
Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic... Read More
EMA validates Gilead’s MAA for investigational chronic hepatitis C therapy sofosbuvir/velpatasvir/voxilaprevir
Gilead Sciences, Inc., a biopharmaceutical company, announced that the company’s Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of... Read More